Procizumab is under clinical development by 4TEEN4 Pharmaceuticals and currently in Phase I for Cardiogenic Shock. According to GlobalData, Phase... Likelihood of Approval and Phase Transition Success ...

🤝 We are delighted to start the New Year with exciting news: the successful initiation of our Series C financing round, securing €24 million to support the seamless development of Procizumab ...

Cardiac fibrosis plays an indispensable role in cardiac tissue homeostasis and repair after myocardial infarction (MI). The cardiac fibroblast-to-myofibroblast differentiation and extracellular matrix ...